SCTX

Scribe Therapeutics Inc

28.67

Sep 04 • 3:59 PM ET -2.14 (-6.95%)

29.28

Aftermarket • 7:30 PM ET +0.61 (2.14%)

Healthcare Biotechnology USA Small NASD

Peers: IPSC PRME CMPX PRLD BEAM NTLA LXEO RCKT CRSP ABEO

| Held by: ARKG VTI VXF HLTH TNXT VTWO

Scroll to Statements

Index	-
Market Cap	542.72M
Enterprise Value	663.34M
Income	-
Sales	-
Book/sh	-8.71
Cash/sh	2.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	98
IPO	Jul 24, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	12.62
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.57
Current Ratio	0.57
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.85
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02 AMC
EPS/Sales Surpr.	27.58% -37.97%

Insider Own	36.14%
Insider Trans	224.01%
Inst Own	25.84%
Inst Trans	15.13%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.28%
SMA50	10.93%
SMA200	10.93%
Trades

Shs Outstand	18.93M
Shs Float	12.09M
Short Float	2.35%
Short Ratio	1.12
Short Interest	0.28M
52W High	39.60 -27.60%
52W Low	17.31 65.67%
Volatility	10.80% 14.94%
ATR (14)	3.93
RSI (14)	52.69
Beta	-
Rel Volume	0.58
Avg Volume	254.76K
Volume	148,197

Perf Week	0.81%
Perf Month	12.83%
Perf Quarter	-
Perf Half Y	-
Perf YTD	14.68%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	57.00
Prev Close	30.81
Price	28.67
Change %	-6.95%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-26	Initiated	H.C. Wainwright	Buy	$60
Aug-18-26	Initiated	Wells Fargo	Overweight	$60
Aug-18-26	Initiated	Leerink Partners	Outperform	$37
Aug-18-26	Initiated	Guggenheim	Buy	$50

Sep-02-26 04:05PM	Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.55%
Sep-01-26 08:00AM	Scribe Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.04%
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly) +7.38%
Aug-18-26 09:37AM	Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls (The Fly) +27.94%
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com) -12.38%
04:05PM	Loading…
04:05PM	Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement (GlobeNewswire)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Co-FounderDr. Benjamin L. Oakes Ph.D.

CFO & TreasurerMr. David L. Parrot M.B.A.

Chief Business OfficerDr. Svetlana Lucas Ph.D.

Co-Founder & Scientific AdvisorDr. Jennifer A. Doudna Ph.D.

Co-Founder & VP of External InnovationMr. Brett T. Staahl Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund II, L.P.	10% Owner	Jul 27 '26	Buy	15.00	333,333	4,999,995	2,385,075	Jul 29 07:09 PM
GORDON CARL L	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:50 PM
ORBIMED ADVISORS LLC	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:47 PM
Aghazadeh Behzad	Director	Jul 24 '26	Buy	15.15	2,383,333	36,115,495	3,080,983	Jul 28 09:30 PM
Aghazadeh Behzad	Director	Jul 28 '26	Buy	18.25	7,905	144,266	3,088,888	Jul 28 09:30 PM
Lucas Svetlana	Chief Business Officer	Jul 23 '26	Buy	15.00	3,000	45,000	3,000	Jul 27 09:42 PM
Parrot David	Chief Financial Officer	Jul 23 '26	Buy	15.00	2,666	39,990	1,333	Jul 27 09:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCTX

Scribe Therapeutics Inc

Upgrade your Finviz experience